Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Similarities and differences among antipsychotics.

Carol A Tamminga1

  • 1Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9070, USA. carol.tamminga@UTSouthwestern.edu

The Journal of Clinical Psychiatry
|December 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Associations of social and genetic background variables to neuro-cognitive biomarkers of psychosis.

Biomarkers in neuropsychiatry·2026
Same author

Family-Level Brain Pattern Similarities and Their Clinical Significance in Young Offspring of Individuals With Psychotic Disorders.

Biological psychiatry. Cognitive neuroscience and neuroimaging·2026
Same author

Confirmatory efficacy and safety trial of magnetic seizure therapy versus right unilateral ultra-brief electroconvulsive therapy in depression (CREST-MST): a randomised, double-blind, non-inferiority trial in Canada and the USA.

The lancet. Psychiatry·2026
Same author

Neuroanatomical Deficits in Visual Cortex Subregions of Individuals With Psychosis Spectrum Disorders Linked to Symptoms, Cognition, and Childhood Trauma.

Schizophrenia bulletin·2026
Same author

Signatures of altered free-water and cognition and associations with symptom severity in psychosis spectrum disorders.

Brain, behavior, and immunity·2026
Same author

Does insight improve during the course of psychosis?

Schizophrenia research·2025
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Second-generation antipsychotics offer varied treatments for schizophrenia symptoms, including negative and cognitive deficits. Physician must match patient needs with specific drug characteristics for optimal outcomes.

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia treatment primarily involves antipsychotic medications.
  • Most antipsychotics are equally effective, with clozapine being an exception.
  • Negative symptoms and cognitive deficits in schizophrenia correlate with poor prognosis.

Purpose of the Study:

  • To review the efficacy of second-generation antipsychotics (SGAs) for schizophrenia.
  • To highlight the importance of individualized treatment selection for schizophrenia.

Main Methods:

  • Review of existing literature on antipsychotic drug action and efficacy.
  • Analysis of pharmacological profiles and side effect profiles of SGAs.
  • Discussion of clinical strategies for optimizing schizophrenia treatment.

Related Experiment Videos

Main Results:

  • SGAs may offer better outcomes for negative and cognitive symptoms compared to first-generation antipsychotics.
  • SGAs act via dopamine and serotonin receptor blockade, with varying mechanisms.
  • Individual SGAs possess distinct pharmacological characteristics and side effect profiles.

Conclusions:

  • Optimizing schizophrenia treatment necessitates careful selection of the most appropriate antipsychotic.
  • Switching medications may be required if initial treatment is unsatisfactory.
  • Physicians must align patient-specific needs with the diverse properties of available SGAs.